Abstract
The physicochemical and biological properties of biopharmaceuticals are, in many aspects, different from small molecule drugs. These differences must also be taken into account when evaluating the risk of carcinogenicity in humans. For example, because of their expected biological activity, growth factors or immunomodulators present an inherent risk for potentially enhancing tumor incidence in humans.
Original language | English |
---|---|
Title of host publication | Genotoxicity and Carcinogenicity Testing of Pharmaceuticals |
Publisher | Springer International Publishing AG |
Pages | 125-157 |
Number of pages | 33 |
ISBN (Electronic) | 9783319220840 |
ISBN (Print) | 9783319220833 |
DOIs | |
Publication status | Published - 1 Jan 2015 |
Keywords
- Biotechnology-derived pharmaceuticals
- Carcinogenicity evaluation
- GLP-1 agonists
- Immunomodulators
- Insulin
- Non-clinical evaluation